A randomized, 5-arm dose finding study with a mite allergoϊd SCIT in allergic rhinoconjunctivitis patients.

• The safety and tolerability of a mite allergoϊd subcutaneous allergen immunotherapy (SCIT) product was previously established. The aim of this study was to find the optimally safe and effective allergoϊd dose by evaluating several dosages in patients with house dust mites (HDM)-induced allergic rhinoconjunctivitis (ARC) using a titrated nasal provocation test (TNPT).

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)